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UbiquitinPINK1 and Parkin are gene products that cause genetic recessive Parkinsonism. PINK1 is a protein kinase and
Parkin is a ubiquitin ligase (E3) that links ubiquitin to a substrate. Importantly, under steady state conditions,
the enzymatic activity of Parkin is completely suppressed, but is activatedwhenmitochondria become abnormal.
In 2013 and 2014, biochemical and structure–function analyses revealed a number of critical mechanistic
insights. First, Parkin is a self-inhibitory E3 that suppresses its E3 activity via intramolecular interactions. Second,
in response to a decrease in mitochondrial membrane potential, PINK1 phosphorylates Ser65 in both the Parkin
ubiquitin-like domain and ubiquitin itself. These phosphorylation events cooperate to relieve the Parkin
autoinhibition. Third, activated Parkin forms a ubiquitin–thioester bond at Cys431 to produce a reaction interme-
diate that catalyzes ubiquitylation of substrates on damaged mitochondria. While the molecular mechanism
regulating Parkin enzymatic activity has largely eluded clariﬁcation, a complete picture is now emerging. This
article is part of a Special Issue entitled: Mitophagy.
© 2015 Elsevier B.V. All rights reserved.1. What is ubiquitin ligase E3?
Ubiquitin is a small, well-known protein that functions in signaling
intracellular degradation as well as various other cellular processes.
Ubiquitin covalently bonds target proteins by the successive actions of
three types of enzyme, namely, ubiquitin-activating enzyme (E1),
ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3) (Fig. 1).
The C-terminus of ubiquitin is initially activated to form a high-energy
thioester bond with E1. Next, while the thioester bond activated state
is maintained, ubiquitin is transferred from E1 to a catalytic cysteine
residue in E2. Lastly, ubiquitin is transferred to a substrate by the action
of E3. The bond formed in the last step is an isopeptide bond formed
by condensation of the C-terminal carboxyl group of ubiquitin and the
ε-amino group of the lysine residue on the substrate (there are rare
exceptions though in which the ubiquitin bond is formed with either
the N-terminal amino acid or a cysteine residue of the substrate). The
stability of the resultant lysine conjugated structure is comparable to
that of a branched peptide-bond in themain protein. The ubiquitination
reaction is reversible (various deubiquitination enzymes can remove
the ubiquitin) and repeatable with lysine in the substrate-bonded ubiq-
uitin covalently linking with other ubiquitin molecules to produce a
polyubiquitin chain.
Among the three enzymes, E3 is markedly variable (500 to 1000
types), and is considered a key factor in determining ubiquitylationgy.
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da).substrate speciﬁcity. The mechanism of E3 action has yet to be com-
pletely elucidated; however, because ubiquitylation occurs on artiﬁcial
(pseudo)substrates such as maltose-binding protein (MBP) and S-
peptide only when arranged in close proximity to E3 [1,2], at least one
of the basic roles of E3 is likely to facilitate arrangement of the substrate
near E2 such that the transfer of ubiquitin can proceed. In addition, sev-
eral studies have suggested an allosteric role for E3 in E2 activation [3];
thus, E3 is an enzyme that catalyzes ubiquitin transfer by both arranging
the substrate and activating E2.
E3s have been classiﬁed into three types: RING E3, which possess
a RING-ﬁnger motif, HECT E3, with a HECT domain, and U-box E3 with
a U-box motif. While the RING ﬁnger motif and the U-box motif are
E2-binding motifs, the HECT domain not only interacts with E2 but
also participates in formation of the reaction intermediate by forming
a thioester bond between the active site cysteine and ubiquitin. Based
on amino acid sequence similarity, Parkin has conventionally been cat-
egorized as a RING E3; however, as described below, it has become clear
that Parkin should be designated as a “fourth E3” that possesses charac-
teristics of both RING E3 and HECT E3.2. Enzymatic properties of Parkin
Sporadic Parkinson's disease (PD) is estimated to affect 300 of every
100,000 individuals, thus clariﬁcation of its pathogenic mechanism and
the establishment of fundamental treatments are eagerly awaited.
Abnormal mitochondria have long been suggested as a risk factor for
PD [4]; however, themolecularmechanismunderlying PDdevelopment
Fig. 1. Outline of the ubiquitin reaction. Ubiquitin binds to a substrate through the cascading reactions of three enzymes, E1, E2, and E3. As a result, the fate or function of the substrate is
transformed.
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PD-like diseases (genetic Parkinsonism) that arise from abnormalities
in speciﬁc genes. More than 10 genes have been linked to this form
of the disease to date. Although the pathologies of PD and PD-like dis-
eases do not necessarily coincide completely, they have many common
features. Therefore, we believe that understanding the pathogenic
mechanism underlying genetic Parkinsonism will be helpful in clarify-
ing the pathogenic basis of sporadic PD.
For the past 10 years, we have focused our attention on PINK1 and
Parkin, which are responsible for genetic recessive Parkinsonism.
Because the disease state develops from loss-of-function mutations,
PINK1 and Parkin have a role in preventing the development of Parkin-
sonism. PINK1 is a serine–threonine kinase with a mitochondrial
targeting sequence [5], whereas Parkin is a ubiquitin ligase/E3 with
two characteristic RING ﬁnger motifs, a RING-IBR-RING domain, at
the C-terminus [6,7]. In 2008, Richard Youle's group at the National
Institutes of Health (NIH) published a groundbreaking study [8].
They reported that Parkin is selectively recruited to depolarized
mitochondria following uncoupling with an exogenous reagent such
as carbonyl cyanidem-chlorophenyl hydrazone (CCCP) and that Parkin
then stimulates the autophagic removal of damaged mitochondria [8].
The role of PINK1 in this process was unknown at the time. From
2010 to 2012, we and other groups more fully elucidated PINK1- and
Parkin-mediated functions, and proposed a hypothesis in which the
two proteins cooperate in the segregation and degradation of abnormal
mitochondria such that disruption of this quality control mechanism
resulted in an accumulation of abnormal mitochondria and/or the
overproduction of reactive oxygen species (ROS) thereby leading to
the development of PD.
More speciﬁcally, we elucidated a number of points. 1) PINK1
undergoes constant membrane-potential-dependent processing and
subsequent degradation in healthy mitochondria [9]. 2) When the
membrane potential of mitochondria decreases (i.e., the robustness of
mitochondria is lost), PINK1 bypasses the aforementioned cleavage
and degradation pathway, and accumulates on the outer membrane of
mitochondria and undergoes autophosphorylation of serine 228/402.
This phosphorylation activates PINK1 and transduces the signal as ‘mi-
tochondria are damaged’ [10]. 3) Transmission of this signal to inert
Parkin in the cytosol triggers both translocation of the Parkin protein
to the outer membrane of mitochondria and activation of its latent E3
activity [9]. 4) Parkin-dependent ubiquitination of substrates on thedamaged mitochondria results in the subsequent segregation and deg-
radation of the abnormalmitochondria [9,11]. Other research groups in-
cluding Richard Youle's group independently reported similar
conclusions during 2010 to 2011 [12–16].
With regard to the detailed process of segregation and degradation
of impaired mitochondria, several aspects, such as the involvement
of the proteasome (ATP-dependent protease complex) or autophagy,
have been controversial [17,18]. However, supportive evidence for
the aforementioned hypothesis has been reported independently and
globally, and we believe that the outline of the aforementioned PINK1/
Parkin-mediated process is sufﬁciently reliable.
3. Biochemical re-examination of Parkin E3 activity
While evidence that Parkin functions as an E3 (ubiquitin ligase)
on damaged mitochondria gradually accumulated, the concrete
mechanism by which Parkin is transformed into an active form
remained unclear. In 2013 and 2014, signiﬁcant breakthroughs led to
a more thorough and complete understanding of the molecular basis
of the mechanism underlying Parkin activation.
Rachel Klevit's group (University of Washington) initially reported
an important clue to this activating mechanism in 2011. They analyzed
the catalytic mechanism of human homolog of Drosophila ariadne
(HHARI), which has a RING-IBR-RING domain similar to Parkin. They
found that HHARI forms a thioester bond with ubiquitin at Cys357 on
the second RING ﬁnger motif, and this ubiquitin–thioester bond serves
as a reaction intermediate [19]. HHARI thus uses a mechanism of action
with characteristics of both a conventional RING ﬁnger and a HECT
domain, thus the authors proposed that this type of E3 should be termed
a RING/HECT hybrid. While this study was very insightful, formation of
an ester-linked intermediate between Parkin and ubiquitin had not
been demonstrated at that time.
Meanwhile, as described earlier, we had already determined that the
loss of mitochondrial membrane potential was important for Parkin
activation [9]; therefore, we considered the possibility that a Parkin
ubiquitin–thioester intermediate is also formed in association with
the decrease inmitochondrialmembrane potential [20]. Four additional
groups, including Richard Youle's group [21], TonyHunter's group (Salk
Institute) [22], Gary Shaw's and Helen Walden's group (University of
Western Ontario and Cancer Research UK) [23], and Jennifer Johnston's
group (Elan Pharmaceuticals) [24] independently drew the same
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group, Tony Hunter's group, and Jennifer Johnston's group, introduced
amutation into Parkin to convert the unstable thioester bond to a stable
oxyester bond (Cys431 of Parkin, which corresponds to Cys357 in the
active center of HHARI, was replaced with serine). Cells transfected
with this Parkin mutant [Parkin (C431S)] were then treated with CCCP
to decrease the mitochondrial membrane potential. Results from those
experiments indicated that the mutant formed an oxyester bond with
ubiquitin as demonstrated by an apparent increase in molecular weight
following CCCP treatment and sensitivity to NaOH- or hydroxylamine-
treatment [20–24]. In addition, our group and Richard Youle's group
conﬁrmed that the Parkin C431S mutant was unable to ubiquitylate
substrates such as Mfn1/2 on damaged mitochondria, presumably
because the C431S mutant forms a stable oxyester-bond with ubiquitin
and thus behaves as a “dead-end intermediate” that is unable to transfer
ubiquitin to the next substrate [20,21]. Similarly, Jennifer Johnston's
group showed that the Parkin C431S mutation compromises Parkin's
ability to decrease cellular levels of Tom20 [24]. Furthermore, it was
also shown that the ester bond between ubiquitin and the Parkin
(C431S)mutant is formedonly in the presence of PINK1, and is prevented
by either knock-down or knockout of PINK1 [20–22].
In vitro biochemical analyses have also been performed. Using a
cell free assay system, Richard Youle's group revealed formation of the
oxyester between Parkin C431S and ubiquitin [21]. In contrast, our
group, Gary Shaw's group, and Helen Walden's group utilized an
in vitro reconstitution system that used puriﬁed recombinant proteins
(ubiquitin, E1, E2 and Parkin) to demonstrate formation of the oxyester
between recombinant Parkin C431S and ubiquitin [20,23]. To more
convincingly demonstrate that Cys431 is the site at which the ester
bond forms between Parkin and ubiquitin, direct detection of this link-
age between Cys431 of wild-type Parkin and ubiquitin was desirable.
Our attempts proved to be unsuccessful likely because the thioester
bond on Parkin is extremely unstable (indeed, no group has been able
to directly demonstrate this thioester linkage between Cys431 of wild-
type Parkin and ubiquitin). Ultimately, using a ubiquitin-derived chem-
ical probe, ubiquitin-vinylsulfone that has an electrophilic group at
the C-terminus, both Jennifer Johnston's group and our group demon-
strated attack of the probe by the Cys431 thiol group in wild-type
Parkin, and concluded that Parkin Cys431 is indeed the catalytic active
center [20,24].Fig. 2. Schematicmodel for Parkin-catalyzed ubiquitylation. Parkin catalyzes ubiquitylation via
to the substrate. See text for details.When the enzymatic reaction catalyzed by Parkin was reconsidered
based on the above ﬁndings, wewere able to postulate that theﬁrst step
in the reactionmechanism consisted of transfer of the thioester-bonded
ubiquitin on E2 to Cys431 (active center) in the Parkin RING2 domain as
a thioester bond (transthiolation). It then followed that the second step
in the reaction mechanism would involve transfer of ubiquitin on
Cys431 to the lysine residue of the substrate to yield a stable isopeptide
bond via an acyl transfer reaction (Fig. 2).
4. How is the Cys431 catalytic center controlled?
From the viewpoint of ubiquitin–thioester formation at Cys431, our
understanding of the catalytic mechanism of Parkin has greatly
advanced. However, the question of why the E3 function of Parkin
was only activated following a decrease in mitochondrial membrane
potential remained unanswered. In 2013, three groups independently
reported the complete structure of Parkin [24–26]. When these struc-
tural ﬁndings were considered in conjunction with Cys431 as the active
center of Parkin (previous section), the activation mechanism became
apparent.
Parkin is composed of multiple individual domains that are con-
served across species: ubiquitin-like (Ubl), RING0, RING1, IBR, REP,
and an N-terminal RING2 domain (the REP domain was only recently
identiﬁed based on the structural analysis in 2013). Importantly, the
structural analysis revealed: 1) that the REP and RING0 domains cover
the RING1 and the RING2 domains, respectively, and 2) that the active
Cys431 center is located beneath the RING0 domain and is inaccessible
from the cytosol [24–26]. It had already been proposed that Parkin is a
self-inhibiting enzyme that is usually maintained in an inactive state
[9,27,28]. When considering this hypothesis in combination with the
Parkin structure, the following mechanism emerged. Under steady
state conditions, the enzymatically important RING1 domain (blue)
and the RING2 domain (yellowish-red), which contains the Cys431 ac-
tive center (red), are blocked by the inhibitory RING0 domain (green)
and the REP domain (yellow), respectively (Fig. 3). However, whenmi-
tochondria are damaged, the steric hindrances introduced by the RING0
and REP domains are relieved, the catalytic active Cys431 center is
exposed, and Parkin is converted to an active E3 enzyme. In support
of this mechanism, Parkin is partially activated by a mutation that dis-














Relief of auto-inhibition of these sites  
are important for Parkin activation    
Fig. 3. Structure of Parkin. A diagram showing the interrelationship among the Parkin domains. The emphasized portions in the ﬁgure are the self-inhibitory sites. These diagrams were
prepared with the help of Dr. Hideaki Shimizu of RIKEN.
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the interaction between the RING0 domain and the RING2 domain
(F463Y) [24–26].
5. Relationship between Parkin activation and PINK1
The next question was why are the inhibitory domains, such as
the RING0 domain and the REP domain, relaxed when mitochondria
are damaged? Undoubtedly, the most important upstream factor that
connects Parkin and damaged mitochondria is PINK1. Miratul Muqit's
group (University of Dundee) and Nobutaka Hattori's group (Juntendo
University), reported that PINK1 is a protein kinase that phosphorylates
Parkin Ser65 [29,30]. We also independently determined that Ser65 in
the Parkin Ubl domain undergoes PINK1-dependent phosphorylation
and that this event is important for formation of the ubiquitin-ester
bond at Cys431 of Parkin [20]. Although ten Parkin phosphorylation
sites had been reported at the time, we were unable to detect or ﬁnd
any signiﬁcance in phosphorylation of sites other than Ser65 in our
assay system. We thus think that the only signiﬁcant phosphorylation
site in Parkin is Ser65 [20].
The next mechanistic question sought to determine if phosphoryla-
tion of Parkin Ser65 promoted conversion of Parkin to the active form.
We found that formation of the oxyester intermediate between Parkin
and ubiquitin is inhibited by an unphosphorylatable S65A mutation
in Parkin. On the other hand, the introduction of phosphorylation-
mimetic mutations such as S65D or S65E was insufﬁcient for CCCP-
independent formation of the oxyester intermediate between Parkin
and ubiquitin equivalent to WT Parkin [20]. These results suggested
that the molecular mechanism underlying Parkin activation could not
adequately be explained by PINK1-catalyzed phosphorylation of Parkin
Ser65 alone; in other words, the phosphorylation of Ser65 of Parkin is
necessary but insufﬁcient for the activation of Parkin.
6. Ubiquitin phosphorylated by PINK1 is an activator for Parkin
As described above, the involvement of an unknown PINK1 sub-
strate in Parkin activation was suggested. Therefore, we attempted
to identify this novel PINK1 substrate that activates Parkin. In 2014,
our group, as well as Richard Youle's group and Miratul Muqit's
group, independently discovered that the molecule in question was,surprisingly, PINK1 phosphorylated ubiquitin [31–33]. Despite minor
differences among the respective publications, for example the contribu-
tion of Parkin Ser65 phosphorylation on Parkin activation (details are
described below), the three groups drew the same conclusion. Kane
et al. reported that sole expression of phosphomimetic ubiquitin
(S65D) assists in formation of the ubiquitin-oxyester intermediate on a
Parkin S65A/C431S mutant (unphosphorylatable, oxyester-formation
mutant) even in the absence of CCCP treatment, thus they suggested
that Ser65-phosphorylated ubiquitin is sufﬁcient for Parkin activation,
and that phosphorylation of Ser65 in Parkin is less important [31]. In
contrast, we revealed that sole expression of a phosphomimetic ubiqui-
tin (S65D) cannot support auto-ubiquitylation of GFP-Parkin (wild type)
in the absence of CCCP treatment, and that a phosphomimetic mutation
of Parkin itself is required for CCCP-independent auto-ubiquitylation
of GFP-Parkin. We thus contend that phosphorylation of Ser65 in both
Parkin and ubiquitin are important for Parkin activation [33]. While
further analysis will be required to clarify the contribution of Parkin
Ser65 phosphorylation on Parkin activation, the three papers agree
that PINK1 is a ubiquitin kinase and that phosphorylated ubiquitin
functions as an activator of Parkin [31–33].
Ser65, the position at which Parkin is phosphorylated by PINK1, is
localized in the N-terminal portion of the Ubl domain. As the name
“ubiquitin-like” suggests, the amino acid sequence and structure of
the Ubl domain are very similar to that of ubiquitin, and Ser65 is well
conserved between the two molecules. Using this as our starting clue,
we demonstrated: 1) that ubiquitin is phosphorylated by PINK1 follow-
ing a decrease in mitochondrial membrane potential; 2) that this phos-
phorylation occurs at Ser65 of ubiquitin; and 3) that phosphorylated
ubiquitin activates the E3 function of Parkin both in cells and in vitro
[27]. Interestingly, phosphorylated ubiquitin accelerates discharge of
ubiquitin from the E2 ~ ubiquitin thioester complex depending on the
presence of the Parkin catalytic cysteine (Cys431), revealing that the ac-
tivationmechanism is strictly allosteric and that Parkin Cys431 becomes
accessible when incubated with phosphorylated ubiquitin. These data
suggest that phosphorylated ubiquitin activates Parkin by relieving
the inhibitory effect of the RING0 domain against the Cys431 containing
RING2 domain.
The literature is abundantwith ubiquitin studies; however, nonepre-
dicted that ubiquitin per se, which is widely used as a post-translational
modiﬁcation factor in cells, would be phosphorylated and play a critical
Fig. 4. Model for the function of PINK1/Parkin/ubiquitin during mitochondrial quality control. See text for details. PINK1 and Parkin act cooperatively to ubiquitylate substrates on
depolarized mitochondria. Although we do not know whether phosphorylated ubiquitin is preferentially conjugated to the substrate by Parkin in comparison to unmodiﬁed ubiquitin,
we have shown that Parkin conjugates both phosphorylated and un-phosphorylated ubiquitins to the substrate on depolarizedmitochondria [33]. Dysfunction of this mechanism causes
an accumulation of abnormal mitochondria and/or the overproduction of reactive oxygen species (ROS), eventually leading to the development of Parkinsonism.
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Although our mentor, Dr. Keiji Tanaka, and we have studied ubiquitin
for a long time, this conclusion came as a real surprise. Fortunatelymul-
tiple good reviews have been published, and readers are encouraged to
refer to them for further insights regarding ubiquitin phosphorylation
[34–39].
7. Conclusion
The years 2013 and 2014 marked important milestones in our
understanding of the Parkin activation mechanism. Biochemical and
structural biological studies from at least seven groups, including ours,
determined a number of points in the mechanism. 1) Cys431 is the
enzymatic active center of Parkin. This cysteine forms a thioester bond
with ubiquitin, which is then transferred to the lysine residue of
the substrate via an acyl transfer reaction. 2) The Cys431 containing
RING2 domain and the E2-binding RING1 domain are structurally
inhibited by the RING0 and the REP domains, respectively. 3) PINK1-
catalyzed phosphorylation at Ser65 of the Ubl domain of Parkin and
ubiquitin relieve the aforementioned autoinhibition of Parkin, which
converts Parkin to the active form. Thus, our understanding of how
PINK1 and Parkin mediate degradation of damaged mitochondria
has moved one step forward (see Fig. 4); however, many questions
regarding PINK1 and Parkin-catalyzed mitochondrial quality control
remained unresolved. For example, the interaction domain between
Parkin and phosphorylated ubiquitin is not yet known, although a puta-
tive phospho-peptide binding site on Parkin has been suggested [25].
In addition, direct evidence for a structural change in Parkin by phos-
phorylated ubiquitin has not been demonstrated. The identity of the
factor that links Parkin-catalyzed ubiquitylation to membrane trafﬁck-
ing and/or the autophagic pathway also remains to be unequivocally
demonstrated, and the involvement of autophagic receptors such as
p62 are controversial [11,14,40–42]. We are very interested in how
future research endeavors will further illuminate these topics.
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